TITLE

AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease

AUTHOR(S)
Xue, Y.-Q.; Ma, B.-F.; Zhao, L.-R.; Tatom, J. B.; Li, B.; Jiang, L.-X.; Klein, R. L.; Duan, W.-M.
PUB. DATE
January 2010
SOURCE
Gene Therapy;Jan2010, Vol. 17 Issue 1, p83
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We have recently shown that intrastriatal injection of recombinant human erythropoietin (EPO) protects dopaminergic (DA) neurons in the substantia nigra (SN) from 6-hydroxydopamine (6-OHDA) toxicity in a rat model of Parkinson's disease. However, systemic administration of EPO did not protect nigral DA neurons, suggesting that the blood–brain barrier limits the passage of EPO protein into the brain. In the present study, we used an adeno-associated viral (AAV) serotype 9 (AAV9) vector to deliver the human EPO gene into the brain of 6-OHDA-lesioned rats. We observed that expression of the human EPO gene was robust and stable in the striatum and the SN for up to 10 weeks. EPO-immunoreactive (IR) cells were widespread throughout the injected striatum, and EPO-IR neurons and fibers were also found in the ipsilateral SN. Enzyme-linked immunosorbent assay and western blot analyses exhibited dramatic levels of EPO protein in the injected striatum. As a result, nigral DA neurons were protected against 6-OHDA-induced toxicity. Amphetamine-induced rotational asymmetry and spontaneous forelimb use asymmetry were both attenuated. Interestingly, we also observed that intrastriatal injection of AAV9-EPO vectors led to increased numbers of red blood cells in peripheral blood. This highlights the importance of using an inducible gene delivery system for EPO gene delivery.
ACCESSION #
47342927

 

Related Articles

  • Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to l-DOPA. Ionov, Ilya; Severtsev, Nicholas // Psychopharmacology;Sep2012, Vol. 223 Issue 2, p191 

    Rationale: In rodents and dog, histamine induces catalepsy, a dopamine-dependent phenomenon that resembles the extrapyramidal signs of Parkinson's disease (PD). Histamine was also found to damage the dopaminergic neurons in rat substantia nigra. These facts, as well as an increase in brain...

  • Investigating Bacterial Sources of Toxicity as an Environmental Contributor to Dopaminergic Neurodegeneration. Caldwell, A.; Tucci, Michelle L.; Armagost, Jafa; Hodges, Tyler W.; Chen, Jue; Memon, Shermeen B.; Blalock, Jeana E.; DeLeon, Susan M.; Findlay, Robert H.; Ruan, Qingmin; Webber, Philip J.; Standaert, David G.; Olson, Julie B.; Caldwell, Guy A. // PLoS ONE;2009, Vol. 4 Issue 10, p1 

    Parkinson disease (PD) involves progressive neurodegeneration, including loss of dopamine (DA) neurons from the substantia nigra. Select genes associated with rare familial forms of PD function in cellular pathways, such as the ubiquitinproteasome system (UPS), involved in protein degradation....

  • Visualization of nigrosomes-1 in 3T MR susceptibility weighted imaging and its absence in diagnosing Parkinson's disease. GAO, P.; ZHOU, P.-Y.; LI, G.; ZHANG, G.-B.; WANG, P.-Q.; LIU, J.-Z.; XU, F.; YANG, F.; WU, X.-X. // European Review for Medical & Pharmacological Sciences;Dec2015, Vol. 19 Issue 23, p4603 

    OBJECTIVE: To assess the imaging features of nigrosomes-1 in the substantia nigra through 3T MR susceptibility weighted imaging (SWI) and its disease-specific changes for the diagnosis of Parkinson's disease (PD). PATIENTS AND METHODS: A total of 116 subjects were included in this study and...

  • The ultra early diagnosis of Parkinson's disease by the enhanced substantia nigra echo. ZHUANG, J.-J.; ZHENG, Y.-H.; XU, X.-W.; ZHOU, L. // European Review for Medical & Pharmacological Sciences;Dec2015, Vol. 19 Issue 23, p4621 

    OBJECTIVE: Our objective is to determine the value of enhanced substantia nigra echo in the diagnosis of Parkinson's disease by analyzing the intensity and area of substantia nigra echo by transcranial Doppler sonography (TCS). PATIENTS AND METHODS: 36 patients diagnosed as ultra early stage...

  • A Case of Hemiparkinsonism following Ischemic Lesion of the Contralateral Substantia nigra: A PET Study. Orimo, S.; Amino, T.; Tanak, H.; Mitani, K.; Ishiwata, K.; Ishii, K. // European Neurology;2004, Vol. 51 Issue 3, p175 

    Parkinsonism associated with focal lesions localized in the substantia nigra (SN) has rarely been reported. Careful investigation of such patients can provide important information to facilitate understanding of the pathophysiology of parkinsonian features such as tremor at rest and cogwheel...

  • Detection of Recombinant Epoetin and Darbepoetin Alpha after Subcutaneous Administration in the Horse. Lasne, Françoise; Popot, Marie-agnes; Varlet-Marie, Emmanuelle; Martin, Laurent; Martin, Jean-Antoine; Bonnaure, Yves; Audran, Muchel; De Ceaurruz, Jacques // Journal of Analytical Toxicology;Nov/Dec2005, Vol. 29 Issue 8, p835 

    The paper proposes a direct detection method for anti-doping control of recombinant human erythropoietin (rHuEPO) abuse in racehorses. The method involves screening of plasma by an enzyme-linked immunosorbent assay specific for human EPO and confirmation in urine samples by characterization of...

  • Iron in the brain. Galazka-Friedman, Jolanta; Friedman, Andrzej; Bauminger, Erika R. // Hyperfine Interactions;Feb2009, Vol. 189 Issue 1-3, p31 

    The results of our studies of iron in three brain structures, substantia nigra (SN), globus pallidus (GP), and hippocampus (Hip), are presented. Mössbauer spectroscopy, electron microscopy and ELISA (enzyme-linked immuno-absorbent assay) were applied. Mössbauer studies show that most of...

  • Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Piccini, Paola; Brooks, David J.; Björklund, Anders; Gunn, Roger N.; Grasby, Paul M.; Rimoldi, Ornella; Brundin, Patrik; Hagell, Peter; Rehncrona, Stig; Widner, Håkan; Lindvall, Olle // Nature Neuroscience;Dec99, Vol. 2 Issue 12, p1137 

    Synaptic dopamine release from embryonic nigral transplants has been monitored in the striatum of a patient with Parkinson's disease using [[sup 11]C]-raclopride positron emission tomography to measure dopamine D[sub 2] receptor occupancy by the endogenous transmitter. In this patient, who had...

  • Substantia nigra pars reticulata is a highly potent site of action for the behavioral effects of the D1 antagonist SCH 23390 in the rat. Trevitt, J.T.; Carlson, B.B.; Nowend, K.; Salamone, J.D. // Psychopharmacology;2001, Vol. 156 Issue 1, p32 

    Rationale: Considerable evidence indicates that dopaminergic drugs, including drugs that act on D1 receptors, exert their effects by actions on forebrain dopamine terminal regions. Nevertheless, anatomical studies also have demonstrated that there is a high concentration of D1 receptors in the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics